Chemopreventive properties and mechanisms of N-Acetylcysteine. The experimental background.
The thiol N-acetylcysteine (NAC), now under clinical trial for cancer chemoprevention both in Europe (project Euroscan) and in the US (National Cancer Institute), has been shown during the past decade to exert protective effects in a variety of experimental test systems. NAC inhibited spontaneous mutagenicity and that induced by a number of chemical compounds and complex mixtures. Moreover, NAC significantly decreased the incidence of neoplastic and preneoplastic lesions induced by several chemical carcinogens in rodents (mice, rats, hamsters), e.g., in lung, trachea, colon, liver, mammary gland, Zymbal gland, bladder and skin. Our studies provided evidence that multiple mechanisms contribute to NAC antimutagenicity and anticarcinogenicity. They include extracellular mechanisms, such as detoxification of reactive compounds due to the nucleophilic and antioxidant properties of NAC, inhibition of nitrosation products, and enhancement of thiol concentration in intestinal bacteria; trapping and enhanced detoxification of carcinogens in long-lived non-target cells, such as erythrocytes and bronchoalveolar lavage cells; mechanisms working in the cytoplasm of target cells, such as replenishment of GSH stores, modulation of metabolism of mutagens/carcinogens, blocking of electrophiles, and scavenging of reactive oxygen species; and nuclear effects, such as inhibition of DNA adduction by metabolites of carcinogens, inhibition of "spontaneous" mutations, attenuation of carcinogen-induced DNA damage, and protection of nuclear enzymes, such as poly(ADP-ribose) polymerase.(ABSTRACT TRUNCATED AT 250 WORDS)
Institute of Hygiene and Preventive Medicine, University of Genoa, Italy.
S
S
De Flora
C F
CF
Cesarone
R M
RM
Balansky
A
A
Albini
F
F
D'Agostini
C
C
Bennicelli
M
M
Bagnasco
A
A
Camoirano
L
L
Scatolini
A
A
Rovida
D000111:Acetylcysteine / Q000627:therapeutic use*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000737:chemistry; D006224:Cricetinae; D003593:Cytoplasm / Q000187:drug effects; D006801:Humans; D008658:Inactivation, Metabolic; D051379:Mice; D009152:Mutagenicity Tests; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D051381:Rats
D016588:Anticarcinogenic Agents; D015415:Biomarkers; D000111:Acetylcysteine